Pioglitazone Tablet
Product Images NDC 70518-2129

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Pioglitazone (NDC 70518-2129). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Pioglitazone is a prescription drug manufactured by Rising Pharma, Inc. It requires a prescription to purchase as denoted in "Rx Only" label. The medicine is packaged in a bottle with NDC number 70518-2129-00 with an expiration date (not available) and a LOT number (not available) indicated on the label. The source NDC number is 57237-0220-05. The package does not give explicit directions for use of the medicine but advises users to see package insert. The drug should be stored in a cool and dry place between 20-26°C (63-77°F); excursions permitted up to 15-30°C (59-86°F) as specified by USP guidelines. The package was repackaged by RemedyRepack Inc located at Indiana, PA 15701. The package label warns that the medicine should be kept out of the reach of children.*
FDA Label Image

Figure 1. Mean Change From Baseline For Hba1c In A 26-week Placebo-controlled Dose-ranging Study (observed Values) (Pioglitazone Fig1)

Figure 1. Mean Change From Baseline For Hba1c In A 26-week Placebo-controlled Dose-ranging Study (observed Values) (Pioglitazone Fig1)
The image is a figure showing the mean change from baseline for HbAlc in a 26-week placebo-controlled dose-ranging study. There are three different doses represented by three different lines: 15mg, 30mg, and 45mg. The x-axis shows time in weeks, while the y-axis shows the mean percentage change from baseline. The observed values indicate a substantial decrease in HbAlc over the 26-week period for all three doses, with the greatest improvement seen in the 45mg group.*
FDA Label Image

Chemical Structure (Pioglitazone Str)

Chemical Structure (Pioglitazone Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.